Deutsche Märkte geschlossen
DAX
17.737,36 -100,04 (-0,56%) Euro Stoxx 50
4.918,09 -18,48 (-0,37%) Dow Jones 30
37.986,40 +211,02 (+0,56%) Gold
2.406,70 +8,70 (+0,36%) EUR/USD
1,0661 +0,0015 (+0,14%) Bitcoin EUR
60.382,82 +718,26 (+1,20%)
Lexaria Bioscience Corp. (LEXX)
NasdaqCM - NasdaqCM Echtzeitpreis. Währung in USD
Zur Watchlist hinzufügen
Börsenschluss: 04:00PM EDT
Nachbörse:
| Kurs Vortag | 2,2500 |
| Öffnen | 2,2600 |
| Gebot | 2,1200 x 100 |
| Briefkurs | 2,2400 x 200 |
| Tagesspanne | 2,1700 - 2,2900 |
| 52-Wochen-Spanne | 0,6490 - 6,8500 |
| Volumen | |
| Durchschn. Volumen | 495.529 |
| Marktkap. | 28,349M |
| Beta (5 J., monatlich) | 0,95 |
| Kurs-Gewinn-Verhältnis (roll. Hochrechn.) | N/A |
| EPS (roll. Hochrechn.) | -0,6700 |
| Gewinndatum | 12. Juli 2024 - 16. Juli 2024 |
| Erwartete Dividende & Rendite | N/A (N/A) |
| Ex-Dividendendatum | N/A |
| 1-Jahres-Kursziel | 11,00 |
ACCESSWIRELexaria to Evaluate Impact of DehydraTECH on Oral Performance of GLP-1 drugs used in products such as Ozempic, Wegovy and Rybelsus, Alone or Together with DehydraTECH-CBD
Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces its intention to launch new human and animal studies to examine DehydraTECH™-processed glucagon-like peptide-1 ("GLP-1") drugs such as, but not limited to, semaglutide sold under Novo Nordisk's brand names Ozempic®, Wegovy® and Rybelsus®, for purposes of improved bioavailability, cost-effectiveness, tolerability,
